The IKZF5 Knockout A-549 Polyclonal Cells are a heterogeneous CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line. This pool carries targeted IKZF5 gene disruptions, enabling loss-of-function studies in an epithelial background. The polyclonal format reflects natural variation in editing outcomes, providing a robust system to assess IKZF5 deficiency without clonal isolation. Designed for advanced research, this model supports investigations into gene function, signaling networks, and the role of IKZF5 in lung carcinoma biology.
The A-549 cell line, derived from human lung adenocarcinoma, is a widely used model of alveolar basal epithelial cells. These cells retain key characteristics of type II pneumocytes and are extensively employed in cancer, drug development, and respiratory disease research. Their tumorigenic origin and documented signaling networks make them suitable for examining functional consequences of gene perturbations such as IKZF5 knockout. The epithelial context provides a platform for studying non-canonical roles of hematopoietic transcription factors in solid tumors.
IKZF5 encodes a zinc finger transcription factor of the IKAROS family, repressing target genes via corepressor complexes. IKZF5 is regulated by Notch receptor signaling: upon ligand engagement, the Notch intracellular domain (NICD) complexes with RBPJ and MAML, modulating IKZF5 activity. TCR signaling and cytokines like IL-2 also influence IKZF5 expression. IKZF5 interacts with IKZF1?CIKZF4 and recruits chromatin modifiers including HDAC1, SIN3A, and NUPR1 to repress promoters of CDKN1A and BCL2. Disrupting this repressor function allows target locus derepression, offering insight into IKAROS-mediated transcriptional control.
In A-549 lung adenocarcinoma cells, IKZF5 knockout abrogates IKAROS-dependent repression, potentially reactivating proliferation- and apoptosis-controlling genes. Although predominantly studied in immune development, IKZF5 expression in epithelial cells suggests unexplored tumor-suppressive roles. The polyclonal nature mimics tumor genetic diversity, enhancing physiological relevance. Researchers can evaluate IKZF5 loss-of-function across editing efficiencies, enabling robust comparisons with wild-type controls and nuanced interpretation in a carcinoma background.
This knockout product suits a broad range of experimental strategies. Functional characterization can use western blotting and RT-qPCR for targets like CDKN1A and BCL2. Global transcriptome profiling via RNA-seq reveals pathway perturbations, while proliferation and colony formation assays assess tumorigenic phenotypes. Flow cytometry-based apoptosis assays further elucidate IKZF5’s role in cell survival. These assays support drug screening for IKAROS-targeted therapies and mechanistic studies in lung cancer. For further technical details or customized applications, please contact Ascent Research.
